6588 POSTER

Phase 3 Dose Selection for Ganitumab (AMG 479) in Pancreatic Cancer Based on Clinical Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Assessments

J. Lu[1], M. Kuchimanchi[1], R. Tang[2], H. Deng[2], H. Kindler[3], C. Fuchs[4], S. Suzuki[5], J. Gansert[6], E. Loh[7], M. Zhu[1]. *[1]Amgen Inc., Pharmacokinetics & Drug Metabolism, Thousand Oaks CA, USA; [2]Amgen Inc., Biostatistics, Thousand Oaks CA, USA; [3]University of Chicago, University of Chicago Medical Center, Chicago, USA; [4]Dana-Farber Cancer Institute, Center for Gastrointestinal Cancer, Boston, USA; [5]Amgen Inc., Biostatistics, South San Francisco, USA; [6]Amgen Inc., Oncology, Thousand Oaks, USA; [7]Amgen Inc., Oncology, South San Francisco, USA*

Background: Ganitumab (gmab) is an investigational, fully human monoclonal antibody against IGF1R. Population pharmacokinetic (PK) and PK/pharmacodynamic (PK/PD) assessments were performed to support gmab phase 3 (P3) study design in pancreatic cancer (PC) pts.
Methods: PK of gmab was characterized using concentration data from 4 Amgen-sponsored studies: two P1 studies (n = 64 pts) in advanced solid tumours (gmab monotherapy and gmab + gemcitabine [G]; ClinicalTrials.gov ID: NCT00562380 and NCT00974896) and 2 randomized, placebo-controlled P2 studies, one in breast cancer (BC, n = 104, gmab + exemestane [E] or fulvestrant [F] or placebo + E or F; NCT00626106) and one in PC (n = 35, gmab + G or placebo + G; NCT00630552). PK/PD analysis of the P2 PC study was performed with data from the gmab 12 mg/kg + G and placebo + G arms (~40 pts/arm). Effect of steady-state area under the concentration-time curve (AUC_{ss}) on overall survival (OS) and progression-free survival (PFS) was evaluated using a proportional Cox regression model. Kaplan–Meier estimates of PFS and OS were compared between pts with AUC_{ss} $\geqslant$median vs ss groups). Relationships between the gmab AUC_{ss} groups and adverse event (AE) rate and laboratory changes were investigated. Effects of confounding factors on the association between OS or PFS and AUC_{ss} were assessed by multivariate analyses. Potential P3 doses for gmab were explored with Monte Carlo simulations.
Results: The estimated gmab clearance (CL) was 0.0481, 0.0296, and 0.0283 L/h and the central volume distribution (Vc) was 5.13, 3.77, and 3.85 L for pts with PC, BC, and other solid tumours, respectively. The higher CL and larger Vc in PC pts resulted in ~40% lower gmab AUC_{ss} than in non-PC pts. In the high and low AUC_{ss} groups (median AUC_{ss}: 19.2 mg.h/mL), OS was longer in the high AUC_{ss} group (16 vs 4.7 months). There was a positive association between AUC_{ss} and both OS ($P < 0.001$) and PFS ($P < 0.001$). The effect of AUC_{ss} on PFS and OS remained significant after adjusting for potential prognostic factors including those associated with CL of gmab. The overall incidence of AEs was similar between the high and low AUC_{ss} groups. The incidences of grade 3/4 hyperglycemia and thrombocytopenia were slightly higher in the high AUC_{ss} group. There was no strong evidence of an association between AUC_{ss} and selected laboratory values (neutrophils, platelets, AST, ALT, fasting glucose). Simulations projected improved OS and PFS with 20 mg/kg vs 12 mg/kg gmab.
Conclusions: The reduced exposure of gmab in PC and the association between increased AUC_{ss} and improved clinical outcomes in PC support evaluation of the gmab 20 mg/kg dose. 12 and 20 mg/kg gmab are being evaluated in a P3 trial in PC (GAMMA: Gemcitabine and AMG 479 for Metastatic Adenocarcinoma of the Pancreas; NCT01231347).

6589 POSTER

How Much Chemotherapy Are Patients With Advanced Pancreatic Cancer Receiving at the End of Life?

K. Feuerlein[1], S. De Dosso[1], F.O. Castillo[2], M. Frigerio[3], M. Ghielmini[1], P. Saletti[1]. *[1]Oncology Institute of Southern Switzerland, Medical Oncology, Bellinzona, Switzerland; [2]National Oncology Institute, Medical Oncology, Panama City, Panama; [3]Internal Medecine Department University of Lausanne (CHUV), Medical Oncology, Lausanne, Switzerland*

Background: Advanced pancreatic adenocarcinoma (APC) is a chemo-resistant cancer with poor prognosis. We evaluated the use of chemotherapy in the last months of life.
Methods: Retrospective analysis of patients with APC treated from 1993 to 2010 at the Oncology Institute of Southern Switzerland. Clinical and laboratory parameters starting from 28 days prior to the last administration of chemotherapy were recorded, including ECOG performance status, presence of ascites, haemoglobin (Hb), white blood cell (WBC) count, platelets, total bilirubin, albumin, LDH, C-reactive protein (C-rp) and Ca 19.9.
Results: The characteristics of the 231 patients were: males/females 53%/47%; metastatic/locally advanced disease 80%/20%; median age 66 years (range 32−85). Median overall survival calculated from diagnosis was 6.1 months (95% CI: 5.1−7.2); death was due to disease progression in all cases. At last chemotherapy administration, ECOG performance status was 0−1 in 38% and 2−3 in 62%. Fifty-nine percent of pts received first-line chemotherapy only (gemcitabine in 70%; gemcitabine-based doublets or 5FU in 30%), whilst 32%, 8% and 1% had second- (5FU 37%; oxaliplatin-based doublets 57%; phase I trial 6%), third- and fourth-line therapy (single agent or phase I trial), respectively. The interval between last chemotherapy administration and death was <4 weeks in 24%, $\geqslant$4−12 weeks in 47% and >12 weeks in 29%. Table 1 summarizes the proportion of patients treated according to the interval between last chemotherapy and death refered to chemotherapy line. Median survival from last chemotherapy delivery to death was 7.5 weeks (95% CI 6.7−8.4). In univariate analysis, presence of ascites, elevated WBC, total bilirubin, LDH, C-rp and Ca 19.9, and reduced albumin were found to predict shorter survival ($p < 0.05$ for each). However, none of them was an independent predictor in the multivariate analysis.
Conclusions: A significant proportion of patients with APC received chemotherapy in the last months of life. In our study, none of the clinical and laboratory parameters recorded 28 days priorto the last chemotherapy delivery were found to predict survival.

Table 1.

Last line	<4 weeks	$\geqslant$4−12 weeks	>12 weeks
1st line (n = 137)	27%	48%	25%
2nd line (n = 74)	20%	47%	33%
3th line (n = 18)	22%	39%	39%
4th line (n = 2)	0	50%	50%

6590 POSTER

Phase IIa Study of TP300 as 1st-line Monotherapy in Patients With Advanced Gastric (GC) or Gastro-oesophageal Junction (GOJ) Carcinoma

T.R.J. Evans[1], D.J. Propper[2], D.A. Anthoney[3], W. Mansoor[4], M.M. Eatock[5], D. Ford[6], R. Agarwal[7], D. Thomson[8], M. Miwa[9]. *[1]Cancer Research UK Beatson Labs, Oncology & Applied Pharmacology, Glasgow, United Kingdom; [2]St Bartholomew's Hospital, Barts Cancer Centre, London, United Kingdom; [3]University of Leeds, St James Institute of Oncology, Leeds, United Kingdom; [4]Christie Hospital, Medical Oncology, Manchester, United Kingdom; [5]Belfast City Hospital, Belfast Cancer Centre, Belfast, United Kingdom; [6]University Hospital, Clinical Oncology, Birmingham, United Kingdom; [7]Imperial College, Medical Oncology, London, United Kingdom; [8]Chugai Pharma Europe, Chugai Pharma, London, United Kingdom; [9]Chugai Pharmaceuticals Ltd, Drug Development, Tokyo, Japan*

Background: TP300, a novel topoisomerase I inhibitor, had manageable toxicity in a Phase I study, in which 3 of 12 patients at the Maximum Tolerated Dose (10 mg/m^2) had dose-limiting toxicity. Consequently, 8 mg/m^2 was chosen as the starting dose in subsequent studies. The primary objective of this Proof of Concept study was to determine the objective response rate of TP300 in patients with advanced gastric (GC) or gastro-oesophageal junction (GOJ) carcinoma. Progression-free survival (PFS), time to progression (TTP), and safety were also determined.
Material and Methods: Eligible patients were those with advanced GC or Siewert Types II or III GOJ carcinoma, previously untreated with chemotherapy for advanced disease, with adequate performance status, hematologic, renal, and hepatic function, and with measurable disease. TP300 was administered as a 1-hour intravenous infusion every 3 weeks for up to 6 cycles at a starting dose of 8 mg/m^2 with intra-patient escalation to 10 mg/m^2 from cycle 2 based on cycle 1 toxicities. Tumour response (RECIST 1.1) was assessed every 6 weeks. Toxicity was recorded using the NCI-CTCAE version 3.0. Using a 2-stage design, a total of 43 patients would be included if there were $\geqslant$3 of 18 patients with objective response in the 1st stage. The study was sponsored by Chugai Pharma Europe Ltd (EudraCT No. 2009-012097-12).
Results: 20 patients (14 males, 6 females), median age 67 years (range 40−82), performance status ECOG 0/1, with GC (14) or GOJ carcinoma (6) received a median of 3 cycles (range 0−6) of TP300. 18 patients were evaluable for response (investigator assessment), 16 on external independent review. 11 patients had a dose increase to 10 mg/m^2 at cycle 2, 2 were decreased to 6 mg/m^2 (investigator decision), and 3/16 continued on 8 mg/m^2. There were no objective responses after 2 cycles of treatment. 12 patients had stable disease for 1−5 months and 4 had progressive disease. Median PFS was 4.1 months (CI [1.6−4.9]), median TTP was 2.9 months (CI [1.4−4.2]). Grade 3/4 toxicities (worst grade all cycles) included 7 patients (35%) with neutropoenia, 4 patients (20%) with anaemia, 2 patients (10%) with thrombocytopenia, 3 patients (15%) with fatigue.